T1	Participants 61 157	myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation
T2	Participants 199 281	90 patients undergoing autologous stem cell transplantation (ASCT) were randomised
T3	Participants 484 645	Both groups underwent ASCT at a median of 8 months from diagnosis and were matched for disease characteristics, prior therapy and pre-ASCT disease responsiveness
